Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 19/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 18/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 18/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 18/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 18/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 18/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175363 | 1.00 | HDAC8 (0.79) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1175294 | 0.93 | HDAC3 (0.79) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1175290 | 0.93 | HDAC3 (0.79) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL2128406 | 0.90 | HDAC3 (0.83) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL2128414 | 0.90 | HDAC3 (0.83) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1547364 | 0.90 | HDAC3 (0.80) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1175199 | 0.88 | HDAC3 (1.00) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1175192 | 0.88 | HDAC3 (1.00) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1176167 | 0.88 | HDAC3 (0.72) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1176169 | 0.88 | HDAC3 (0.72) | HDAC8HDAC6HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115148-B2 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-20140080823-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2014-03-20 | — | — | US | disclosed |
| US-8592444-B2 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.R.L. (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2279187-B9 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC SRL (IT) | 2012-12-12 | — | — | EP | disclosed |
| EP-2279187-B1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC SRL (IT) | 2012-04-25 | — | — | EP | disclosed |
| US-20110039840-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2011-02-17 | — | — | US | disclosed |
| EP-2110377-A1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.r.l. (IT) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039840-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC7, HDAC8, HDAC9 | HDAC8 2/4885HDAC6 21/4885HDAC3 4/4885 |
| US-20140080823-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC7, HDAC8, HDAC9 | HDAC8 2/4885HDAC6 21/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.